Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis

PRIMARY OBJECTIVES:

I. To evaluate the overall hematologic response rate (stringent complete response [sCR] +
amyloid complete response [ACR]+ very good partial response [VGPR] + partial response [PR])
during the first 6 cycles for ibrutinib with bortezomib and dexamethasone added for lack of
response in patients with amyloid light chain (AL).

SECONDARY OBJECTIVES:

I. To evaluate overall hematologic response rate (sCR+ACR+VGPR+PR) of single agent ibrutinib
in patients with AL.

II. To evaluate overall hematologic response rate (sCR+ACR+VGPR+PR) to ibrutinib + bortezomib
and dexamethasone (Vd) in subjects with progressive disease after initial response to single
agent ibrutinib.

III. To describe the toxicities associated with ibrutinib, alone and in combination with Vd,
in patients with AL.

IV. To determine the organ response in AL patients treated with ibrutinib alone and in
combination with Vd.

V. To determine 3 year progression free survival of AL patients on the study.

TERTIARY OBJECTIVES:

I. To characterize health related quality of life of patients. II. To determine the caregiver
and patient disease burden. III. To determine the correlation between cardiac biomarkers and
hematologic response to therapy.

IV. To evaluate the effect of ibrutinib on AL microenvironment. V. To characterize BTK
expression in neoplastic plasma cells. VI. To evaluate the characterization of CD38
expression on neoplastic plasma cells.

OUTLINE:

Patients receive ibrutinib orally (PO) daily (QD) on days 1-28. After 3 courses, patients who
achieve partial response repeat treatment every 28 days for up to 18 courses in the absence
of disease progression or unacceptable toxicity. Patients who do not achieve partial response
after 3 courses continue receiving ibrutinib PO QD on days 1-28. Beginning at course 4,
patients who do not achieve partial response also receive bortezomib subcutaneously (SC) and
dexamethasone PO on days 1, 8, and 15. Treatment repeats every 28 days for up to 18 courses
in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 1 year, and
then every 6 months for 2 years.

Criteria:

- Measurable disease of AL amyloidosis as defined by at least ONE of the following:

- Serum monoclonal protein >= 1.0 by protein electrophoresis

- > 200 mg of monoclonal protein in the urine on 24 hour electrophoresis

- Free light chains (abnormal absolute value, ratio and the dFLC > 5 mg/dL)

Inclusion Criteria:

- Histological diagnosis of AL amyloidosis as based on detection by polarizing
microscopy of green birefringent material in Congo red-stained tissue specimens; the
type must have been confirmed unequivocally

- Must have had one prior line of systemic therapy for AL; Note: patients who do not
achieve at least a PR to frontline therapy in 3 months may be eligible after
discussion with study chair

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2

- Absolute neutrophil count (ANC) >= 1000/mm^3

- Platelet count >= 100,000/mm^3 or >= 50,000/mm^3 if bone marrow involvement
independent of transfusion support in either situation

- Hemoglobin >= 8.0 g/dL

- Total bilirubin =< 1.5 x upper limit of normal (ULN) unless due to Gilbert's syndrome
or of non-hepatic origin

- Aspartate transaminase (AST) =< 3 x upper limit of normal (ULN)

- Alanine aminotransferase (ALT) =< 3 x ULN

- Creatinine =< 3 mg/dL and creatinine clearance (CrCL) >= 25 ml/min

- Negative serum pregnancy test done =< 7 days prior to registration, for persons of
childbearing potential only

- Ability to complete questionnaire(s) by themselves or with assistance

- Ability to provide written informed consent

- Willing to return to enrolling institution for follow-up (during the Active Monitoring
Phase of the study)

- Willing to provide bone marrow and blood samples for correlative research purposes

Exclusion Criteria:

- Any of the following:

- Pregnant persons

- Nursing persons

- Persons of childbearing potential who are unwilling to employ adequate
contraception; Note: persons of childbearing potential and persons able to father
a child who are sexually active must be practicing a highly effective method of
birth control during and after the study consistent with local regulations
regarding the use of birth control methods for subjects participating in clinical
trials; subjects must agree to not donate sperm during and after the study; for
persons of childbearing potential, these restrictions apply for 1 month after the
last dose of study drug; for persons able to father a child, these restrictions
apply for 3 months after the last dose of study drug

- Concomitant high dose corticosteroids (concurrent use of corticosteroids) while on
single agent ibrutinib; EXCEPTION: patients may be on chronic steroids (maximum dose
20 mg/day prednisone equivalent) if they are being given for disorders other than
amyloid, (i.e., adrenal insufficiency, rheumatoid arthritis, etc)

- Active malignancy =< 3 years prior to registration; EXCEPTIONS: Non-melanotic skin
cancer or carcinoma-in-situ of the cervix; Note: if there is a history of prior
malignancy, they must not be receiving other specific treatment for their cancer

- Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
of the investigator, would make the patient inappropriate for entry into this study or
interfere significantly with the proper assessment of safety and toxicity of the
prescribed regimens

- Known history of human immunodeficiency virus (HIV) or active hepatitis C virus or
active hepatitis B virus infection or any uncontrolled active systemic infection

- Any life-threatening illness, medical condition, or organ system dysfunction which, in
the investigator's opinion, could compromise the subject's safety, interfere with the
absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue
risk

- Receiving any other investigational agent which would be considered as a treatment for
AL amyloidosis

- Vaccinated with live, attenuated vaccines =< 4 weeks prior to registration

- Clinically overt multiple myeloma (i.e. original hypercalcemia, renal failure, anemia,
bone lesions [CRAB] criteria); Note: extent of marrow plasmacytosis is not prohibitive

- Clinically significant cardiovascular disease such as uncontrolled or symptomatic
arrhythmias, congestive heart failure, or myocardial infarction =< 6 months prior to
registration, or any class 3 (moderate) or class 4 (severe) cardiac disease as defined
by the New York Heart Association Functional Classification

- NT-ProBNP > 8,500 pg/mL

- Use of strong and moderate CYP3A inhibitors and inducers =< 7 days prior to
registration

- Anticoagulation with warfarin or equivalent vitamin K antagonists (e.g.,
phenprocoumon); Note: use of low molecular weight heparin (or any anticoagulation
agent) is allowed provided there is no history of bleeding (minor or major) =< 12
months prior to registration; the treating physician should discuss the case with the
study chair

- History of stroke or intracranial hemorrhage =< 6 months prior to registration

- Known central nervous system metastasis

- Major surgery or a wound that has not fully healed =< 4 weeks prior to registration

- Surgery or invasive procedure requiring sutures or staples for closure =< 7 days prior
to registration

- Minor procedures (such as a central line placement, needle biopsy, thoracentesis, or
paracentesis) =< 3 days prior to registration